Surgical management of submacular hemorrhage due to n-AMD: a comparison of three surgical methods.
Acute submacular hemorrhage (ASH)
Central foveal thickness (CFT)
Choroidal neovascularization (CNV)
Neovascular age related macular degeneration (n-AMD)
Pars plana vitrectomy (PPV)
Recombinant tissue plasminogen activator (rtPA)
Retinal pigment epithelium (RPE)
Vascular endothelial growth factor (VEGF)
Journal
International journal of retina and vitreous
ISSN: 2056-9920
Titre abrégé: Int J Retina Vitreous
Pays: England
ID NLM: 101677897
Informations de publication
Date de publication:
2020
2020
Historique:
received:
22
11
2019
accepted:
21
06
2020
entrez:
9
7
2020
pubmed:
9
7
2020
medline:
9
7
2020
Statut:
epublish
Résumé
To compare and assess the efficacy of three surgical methods for the treatment of acute submacular hemorrhage (ASH): pneumatic displacement with C2F6, in combination with intravitreal injection of bevacizumab and rtPA, pars plana vitrectomy (PPV) with intravitreal injection of gas (C2F6), bevacizumab and subretinal injection of recombinant tissue plasminogen activator (rtPA), pars plana vitrectomy (PPV) with intravitreal injection of gas (C2F6), bevacizumab and intravitreal injection of recombinant tissue plasminogen activator (rtPA). The study included 85 patients with ASH. In the group without PPV (A), patients were treated with intravitreal injection of C2F6, bevacizumab and rtPA. In the second and third group, patients underwent a PPV, intravitreal injection of bevacizumab, pneumatic displacement with C2F6 and a subretinal (B) or intravitreal (C) injection of recombinant tissue plasminogen activator (rt PA). In group A, mean BCVA increased from preop logMAR 1.41 to 1.05, in group B from 1.46 to 1.28 and in group C from 1.63 to 1.33. In group A, CFT changed from 764 ± 340 μm at time point 0 to 246 ± 153 μm at time point 1, in group B from 987 ± 441 μm to 294 ± 166 μm and in group C from 642 ± 322 μm to 418 ± 364 μm. Patients had an average of 5 injections after surgery. Our study demonstrates that the three methods are equally effective in improving the morphology and the BCVA of patients with ASH.
Sections du résumé
BACKGROUND
BACKGROUND
To compare and assess the efficacy of three surgical methods for the treatment of acute submacular hemorrhage (ASH): pneumatic displacement with C2F6, in combination with intravitreal injection of bevacizumab and rtPA, pars plana vitrectomy (PPV) with intravitreal injection of gas (C2F6), bevacizumab and subretinal injection of recombinant tissue plasminogen activator (rtPA), pars plana vitrectomy (PPV) with intravitreal injection of gas (C2F6), bevacizumab and intravitreal injection of recombinant tissue plasminogen activator (rtPA).
METHODS
METHODS
The study included 85 patients with ASH. In the group without PPV (A), patients were treated with intravitreal injection of C2F6, bevacizumab and rtPA. In the second and third group, patients underwent a PPV, intravitreal injection of bevacizumab, pneumatic displacement with C2F6 and a subretinal (B) or intravitreal (C) injection of recombinant tissue plasminogen activator (rt PA).
RESULTS
RESULTS
In group A, mean BCVA increased from preop logMAR 1.41 to 1.05, in group B from 1.46 to 1.28 and in group C from 1.63 to 1.33. In group A, CFT changed from 764 ± 340 μm at time point 0 to 246 ± 153 μm at time point 1, in group B from 987 ± 441 μm to 294 ± 166 μm and in group C from 642 ± 322 μm to 418 ± 364 μm. Patients had an average of 5 injections after surgery.
CONCLUSION
CONCLUSIONS
Our study demonstrates that the three methods are equally effective in improving the morphology and the BCVA of patients with ASH.
Identifiants
pubmed: 32637155
doi: 10.1186/s40942-020-00228-x
pii: 228
pmc: PMC7331168
doi:
Types de publication
Journal Article
Langues
eng
Pagination
27Informations de copyright
© The Author(s) 2020.
Déclaration de conflit d'intérêts
Competing interestsThe authors declare that they have no competing interests.
Références
Retina. 1996;16(3):183-9
pubmed: 8789855
Am J Pathol. 1993 Sep;143(3):949-58
pubmed: 8362987
Ophthalmology. 2012 Jul;119(7):1388-98
pubmed: 22555112
Br J Ophthalmol. 2010 Jan;94(1):48-53
pubmed: 19946027
Ophthalmology. 2008 Oct;115(10):1837-46
pubmed: 18929163
Trans Am Ophthalmol Soc. 2005;103:98-107; discussion 107
pubmed: 17057793
Graefes Arch Clin Exp Ophthalmol. 2010 Jan;248(1):5-11
pubmed: 19669780
Arch Ophthalmol. 1991 May;109(5):723-9
pubmed: 2025175
Ophthalmology. 2001 Aug;108(8):1485-92
pubmed: 11470706
Retina. 2011 Jan;31(1):36-40
pubmed: 20921929
Retin Cases Brief Rep. 2012 Fall;6(4):400-5
pubmed: 25389941
N Engl J Med. 2011 May 19;364(20):1897-908
pubmed: 21526923
Ophthalmologica. 1999;213(2):97-102
pubmed: 9885385
Graefes Arch Clin Exp Ophthalmol. 1998 Mar;236(3):196-201
pubmed: 9541823
Clin Ther. 2001 Jul;23(7):982-97; discussion 981
pubmed: 11519775
Ophthalmology. 1991 Jan;98(1):23-7
pubmed: 2023727
Graefes Arch Clin Exp Ophthalmol. 2009 Jan;247(1):1-11
pubmed: 18843500
Invest Ophthalmol Vis Sci. 2007 Jun;48(6):2814-23
pubmed: 17525217
Br J Ophthalmol. 2010 Feb;94(2):260-1
pubmed: 20139293
Retina. 2007 Mar;27(3):321-8
pubmed: 17460587
Ann Ophthalmol. 1983 Nov;15(11):1068-74
pubmed: 6651144
Nat Med. 2008 Jul;14(7):731-7
pubmed: 18568034
Graefes Arch Clin Exp Ophthalmol. 2006 Nov;244(11):1421-8
pubmed: 16596407
Am J Ophthalmol. 1982 Dec;94(6):762-73
pubmed: 7180915
Surv Ophthalmol. 1997 Nov-Dec;42(3):195-213
pubmed: 9406367
Am J Ophthalmol. 2000 Apr;129(4):546-7
pubmed: 10764874
Retina. 2010 Jan;30(1):112-6
pubmed: 19834355
Clin Ophthalmol. 2013;7:495-501
pubmed: 23503202
Invest Ophthalmol Vis Sci. 2008 Sep;49(9):4071-7
pubmed: 18421081
Ophthalmology. 1986 Dec;93(12):1581-92
pubmed: 2433658
Br J Ophthalmol. 2006 Apr;90(4):429-31
pubmed: 16547320
Ophthalmology. 2012 Dec;119(12):2537-48
pubmed: 23084240
Am J Ophthalmol. 2010 Feb;149(2):322-329.e1
pubmed: 20103057
Br J Ophthalmol. 2004 Apr;88(4):573-8
pubmed: 15031179
Br J Ophthalmol. 2012 May;96(5):708-13
pubmed: 22174095
Am J Ophthalmol. 2015 Apr;159(4):683-9
pubmed: 25555798
Adv Ther. 1997 Sep-Oct;14(5):275-80
pubmed: 10174620
Retina. 2010 Nov-Dec;30(10):1573-8
pubmed: 21060269
Retina. 2015 Feb;35(2):205-12
pubmed: 25105310
Retina. 2018 Nov;38(11):2103-2117
pubmed: 29697591
Am J Ophthalmol. 2001 Feb;131(2):208-15
pubmed: 11228297
Ophthalmology. 2004 Nov;111(11):1993-2006
pubmed: 15522364
Br J Ophthalmol. 2011 Aug;95(8):1051-7
pubmed: 20813746
Fortschr Ophthalmol. 1991;88(2):135-7
pubmed: 1855730
Arch Ophthalmol. 1998 Oct;116(10):1326-32
pubmed: 9790631
Ophthalmology. 1999 Oct;106(10):1900-6; discussion 1906-7
pubmed: 10519583
Graefes Arch Clin Exp Ophthalmol. 1999 Apr;237(4):273-7
pubmed: 10208258
Ophthalmic Surg. 1991 Oct;22(10):575-82
pubmed: 1961614
Am J Ophthalmol. 1988 Jan 15;105(1):25-9
pubmed: 3337190
Ophthalmology. 2014 Apr;121(4):926-35
pubmed: 24342019
Am J Ophthalmol. 1990 Jan 15;109(1):33-7
pubmed: 2297030
Am J Ophthalmol. 2013 Sep;156(3):524-531.e1
pubmed: 23769197
Ophthalmology. 2004 Jun;111(6):1201-8
pubmed: 15177972
Am J Ophthalmol. 1994 Nov 15;118(5):559-68
pubmed: 7977569
Acta Ophthalmol. 2008 Aug;86(5):490-4
pubmed: 18221499